Agoracom Blog Home

Posts Tagged ‘#Distribution’

CLIENT FEATURE: Mota Ventures MOTA.ca – $29,000,000 in Combined Sales with 2019 EBITDA of Approximately 12.5% $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 12:53 PM on Wednesday, March 11th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

MOTA:CSE

RECENT HIGHLIGHTS

  • Direct to Consumer E-commerce retailer
  • Revenue generating, EBIDTA positive
  • Formalized Joint Venture With Bevcanna Enterprises: Read More
    • Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations
    • Company will provide manufacturing, marketing and distribution infrastructure in the European market.
    • Parties have determined an initial product launch and will provide further details on specific regions and timing once finalize
  • Announced Collaboration for Sativida US Expansion Read More 
    • Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing
    • Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico
  • Entered into Licensing Agreement with Phenome One Read More
    • A privately held full-service live genetic and seed preservation cannabis company.
    • Mota will have full access to Canada’s largest live genetic cannabis library with over 350 cultivars
    • Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands

#1. FIRST CLASS CBD

ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

  • Leader in online CBD sales in North America
  • Crop to package model: US grown CBD hemp
  • Acquired at a 1.5 times revenue valuation
  • Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
  • 2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

  #2. SATIVIDA

ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • Number one search-ranked online retailer in Spain and Mexico
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products

 FIND OUT MORE!

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.

CBD Market on Course to Grow 400% in Europe Alone SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 12:08 PM on Tuesday, March 10th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • Over the next five years, the global CBD market is expected to accelerate to $23.6bn, according to Grand View Research and Europe’s CBD market is set to grow by 400%.

The growth of the CBD market in Europe is thanks to the growing adoption of CBD infused products in industries such as pharmaceuticals, personal care, cosmetics, nutraceuticals, along with medical applications.

CBD is seeing monumental demand in Europe. In Europe alone, the market is on course to grow 400% over the next four years, according to the Brightfield Group.

According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way.

CBD opportunities

The legal cannabis industry continues to expand around the world with major contribution to the market coming from continuous legislative victories in North America and Europe. In particular, legalisation of medical cannabis, and decriminalisation in some countries, has led to a significant decrease in black-market activity, as people are shifting to legally purchasing cannabis for medical as well as recreational use.

In the meantime, local governments reap the benefits through taxation. For instance, the state of California had collected a total of $345.2m in tax revenue from legal cannabis during the first year of regulated sales in 2018. Revenue generated from these taxes encouraged the local governments to fund several development programmes for education and infrastructure.

Medical cannabis

Overall, data by Grand View Research indicates that the medical segment held the dominant revenue share of the cannabis market, accounting for 71.0% in 2019. Medical use of cannabis is strictly categorised as a medicine prescribed by a physician and the distribution of these medicines is regulated by the government. However, by 2027, adult-use is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient.

In recent years, CBD products have swiftly emerged and the growth of the CBD market is largely attributed to various medical applications that are associated with the products. For example, full-spectrum CBD oil is considered to be a great source of Omega 3 and Omega 6; Omega 3 plays a vital role in creating hormones that regulate inflammation as well as contractions and relaxation of arteries.

SOURCE: https://www.healtheuropa.eu/cbd-market-to-grow-400-in-europe/98021/

First Look at the Nine CBD Consumer Archetypes in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 3:47 PM on Thursday, March 5th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Click Here for More Info

Mota large
  • New Frontier Data’s second consumer report in its EU CBD series provides a comprehensive overview of the European CBD consumer experience

New Frontier Data, the global authority in data, analytics and business intelligence on the cannabis industry, publishes the second volume of its EU CBD Consumer Report Series: Segmentation & Archetypes, in partnership with Deep Nature Project and Mile High Labs. Drawing from the groundbreaking surveying of over 3,000 European CBD consumers across 17 European nations, this study results in the most comprehensive consumer archetype report for European CBD consumers to date.

“Europe’s booming consumer interest in CBD and CBD-infused products across the Food & Beverage and Health & Beauty sectors continues to create material B2B and B2C market opportunities. Data-driven insights of both EU and North American CBD consumerism, drawing from not only comparative analysis but also known geo-centric market dynamics and drivers, helps us educate and guide brands on how to address CBD consumer priorities while managing known or expected challenges in this new CBD space,” said New Frontier Data Founder & CEO Giadha Aguirre de Carcer. “This report fills a major gap in business intelligence in the CBD industry not only in Europe, but worldwide, providing new and existing cannabis or hemp industry stakeholders with a uniquely valuable and timely resource.”

Key findings from the report include:

  • 4 of the 5 consumer archetypes have purchased CBD; the Ambivalent & Experimental Consumers instead source CBD from family and friends
  • The largest consumer archetype, the Integrative & Consistent Consumers, are frequent users and staunch believers in CBD’s medical efficacy
  • 26% of Europeans aged 18-34 have tried CBD, compared to 16% of the general population
  • 73% of self-reported consumers claimed CBD has positively affected their quality of life
  • A third (34%) of non-consumers are somewhat or very curious about trying CBD
  • 49% of CBD purchasers who did not themselves consume indicated buying it for a family member
  • Male consumers report spending more on CBD products than female consumers, with more than a third of men (35%) reporting spending €100 or more per month
  • 72% of consumers and 17% of non-consumers considered themselves likely to purchase CBD in the next 6 months
  • Consumers who use CBD primarily for medical reasons were the most frequent CBD consumers, with nearly half (45%) consuming it at least daily

The EU CBD Consumer Report Series: Segmentation & Archetypes is available for FREE Download at: https://newfrontierdata.com/product/the-eu-cbd-consumer-report-2020-segmentation-and-archetypes/

About New Frontier Data:

New Frontier Data is an independent, technology-driven analytics company specializing in the global cannabis industry. It offers vetted data, actionable business intelligence and risk management solutions for investors, operators, researchers and policy makers. New Frontier Data’s reports and data have been cited in over 80 countries around the world to inform industry leaders. Founded in 2014, New Frontier Data is headquartered in Washington, D.C., with additional offices in Denver, CO and London, UK.

New Frontier Data does not take a position on the merits of cannabis legalization. Rather, its mission and mandate are to inform cannabis-related policy and business decisions through rigorous, issue-neutral and comprehensive analysis of the legal cannabis industry worldwide. For more information about New Frontier Data, please visit: https://www.NewFrontierData.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005341/en/

IntellaEquity $IEQ.ca Provides Update on Distribution to Shareholders $SENS.ca $E.ca

Posted by AGORACOM-Eric at 8:17 AM on Friday, April 5th, 2019

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564614/hub/IntellaEquity_Inc._LOGO_v1.jpg
  • Update to the distribution of an aggregate of 25,629,564 common shares in the capital of Sensor Technologies Corp.
  • Due to the fact that the Corporation is incorporated pursuant to the laws of the state of Delaware, it is required to obtain the approval of the Financial Industry Regulatory Authority (“FINRA”) of the United States.
  • The Corporation has made the necessary filings with FINRA in order to obtain its approval. The Corporation will provide updates as they become available.

Toronto, Ontario–(Newsfile Corp. – April 5, 2019) – IntellaEquity Inc. (CSE: IEQ) (the “Corporation”) would like to provide an update with respect to the distribution of an aggregate of 25,629,564 common shares (the “Sensor Shares”) in the capital of Sensor Technologies Corp. (“Sensor”) to the shareholders of the Corporation, as previously announced in its press releases of December 12, 2018 and January 29, 2019.

The Corporation has provided the transfer agent of Sensor with the stock certificate and the necessary documentation to effect the transfer of the Sensor Shares from the Corporation to its shareholders on Feb 22, 2019. However, due to the fact that the Corporation is incorporated pursuant to the laws of the state of Delaware, it is required to obtain the approval of the Financial Industry Regulatory Authority (“FINRA”) of the United States. The Corporation has made the necessary filings with FINRA in order to obtain its approval. The Corporation will provide updates as they become available.

About the Corporation

IntellaEquity is a publicly traded company, it is a diversified investment and venture capital firm focused on providing investors with long-term capital growth by investing in a portfolio of undervalued companies and assets. The investment portfolio may be comprised of securities of both public and private issuers primarily in technology, artificial intelligence, blockchain and may also include investments in certain other sectors, including water, green energy, and alternative energy. Target investments shall encompass companies at all stages of development, including pre-initial public offering and/or early-stage companies requiring start-up or development capital, as well as intermediate and senior companies.

Corporation contact:

Allen Lone
President and CEO
905.275.8111, ext. 226
Email: [email protected]

CLIENT FEATURE: Applied Biosciences $APPB Investment in JUUL Labs Paying Dividends for Shareholders $HTIM $JUUL $WMD

Posted by AGORACOM-Eric at 10:19 AM on Wednesday, February 6th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Received a capital distribution of approximately $186,000 from its investment in JUUL Labs, Inc. (JUUL)
  • The investment remains on the balance sheet under Equity Investments, the company has begun a strategic review of options for the remaining equity stake. 
  • Altria Group Inc. (NYSE: MO) on December 20, 2018 announced it had invested $12.8bn in vaping company Juul Labs, a 35% stake valuing JUUL at $38 billion.
  • APPB also recently acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company with proven revenues
  • Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00
  • APPB has a market cap of $15m US & 10m S/O

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website:www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp.

Client Feature: $IEQ IntellaEquity Sets the 2nd Record Date for Return of Capital $SENS.ca

Posted by AGORACOM-Eric at 10:17 AM on Saturday, February 2nd, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564614/hub/IntellaEquity_Inc._LOGO_v1.jpg
  • The second distribution of 12,805,744 Sensor shares
    will be distributed to holders of Intellaequity shares on record as of Feb. 15, 2019
  • The first distribution of 12,805,753 Sensor shares is to be made to shareholders of Intellaequity on record as of Jan. 15, 2019, as soon as the statutory hold expires.

FULL DISCLOSURE: IntellaEquity Inc. is an advertising client of AGORA Internet Relations Corp.

$IEQ IntellaEquity Sets the 2nd Record Date for Return of Capital $SENS.ca

Posted by AGORACOM-Eric at 12:18 PM on Tuesday, January 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564614/hub/IntellaEquity_Inc._LOGO_v1.jpg
  • The 2nd distribution of 12,805,744 shares of Sensor Technologies Corp. will be distributed to holders of IntellaEquity on record as of February 15, 2019
  • The first distribution of 12,805,753 Sensor Shares is to be made to shareholders of IntellaEquity on record as of January 15, 2019 as soon as the statutory hold expires. The Sensor Shares were subject to a statutory four (4) month hold period that expires on February 3, 201

Toronto, Ontario–(Newsfile Corp. – January 29, 2019) – IntellaEquity Inc. (CSE: IEQ) (the “Corporation” or “IntellaEquity”) announces that, further to its press release of December 12, 2018, the second distribution of 12,805,744 common shares in the capital of Sensor Technologies Corp. (“Sensor”) will be distributed to holders of IntellaEquity shares on record as of February 15, 2019. The first distribution of 12,805,753 Sensor Shares is to be made to shareholders of IntellaEquity on record as of January 15, 2019 as soon as the statutory hold is expires. The Sensor Shares were subject to a statutory four (4) month hold period that expires on February 3, 2019. Upon the expiration of the hold period, the Sensor Shares will be distributed to the holders of IntellaEquity shares as at the respective record dates.

IntellaEquity shareholders are not required to pay for the Sensor Shares they receive by way of the distribution, to tender or surrender their IntellaEquity shares, or to take any other action in connection with the distribution, other than providing a declaration of residency.

No Sensor Shares will be issued to shareholders who are (or are deemed to be) non-residents of Canada. Rather, such Sensor Shares will be delivered to a custodian and non-residents will be required to forward to the custodian the amount of withholding tax that such shareholder is required to pay. In the event that the shareholder does not forward such amount, the custodian shall retain such number of Sensor Shares necessary to cover the amount of the withholding tax payable. The balance of the Sensor Shares will be forwarded to the shareholder.

Shareholders who fail to provide a declaration of Canadian residency in the form that will be provided will be deemed to be a non-resident for these purposes. Canadian shareholders who hold their shares in the Corporation through a brokerage or other account are therefore urged to contact their brokers to avoid being deemed a non-resident.

About SensorSensor

Technologies Corp. is a publicly listed company whose shares trade through the facilities of the CSE under the symbol “SENS”. The company develops non-intrusive asset health monitoring sensor systems for the oil and gas market to help operators track the thinning of pipelines and refinery vessels due to corrosion/erosion, strain due to bending/buckling and process pressure and temperature. The Corporation’s FT fiber optic sensor and corrosion monitoring systems allow cost effective, 24/7 remote monitoring capabilities to improve scheduled maintenance operations, avoid unnecessary shutdowns, and prevent accidents and leaks.

About the Corporation

IntellaEquity is a publicly traded company, it is a diversified investment and venture capital firm focused on providing investors with long-term capital growth by investing in a portfolio of undervalued companies and assets. The investment portfolio may be comprised of securities of both public and private issuers primarily in technology, artificial intelligence, blockchain and may also include investments in certain other sectors, including water, green energy, and alternative energy. Target investments shall encompass companies at all stages of development, including pre-initial public offering and/or early-stage companies requiring start-up or development capital, as well as intermediate and senior companies.

Corporation contact:

Allen Lone
President and CEO

905.275.8111, ext. 226
Email: [email protected]